Ardelyx Inc. (Nasdaq: ARDX) reported positive preclinical data for tenapanor in treating abdominal pain caused by irritable bowel syndrome with constipation but the stock price continued to fall by losing 88 cents to close at $$6.40 as investors locked in profits.
Ardelyx extends losses
October 16, 2017 at 17:52 PM EDT